0 45

Cited 2 times in

Prognostic significance of CA-125 re-elevation after interval debulking surgery in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy

DC FieldValueLanguage
dc.contributor.author김상운-
dc.contributor.author김성훈-
dc.contributor.author김영태-
dc.contributor.author남은지-
dc.contributor.author이용재-
dc.contributor.author이정윤-
dc.contributor.author정영신-
dc.date.accessioned2019-12-18T01:11:57Z-
dc.date.available2019-12-18T01:11:57Z-
dc.date.issued2019-
dc.identifier.issn0748-7983-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/173413-
dc.description.abstractAIMS: We evaluated the prognostic significance of postoperative re-elevation of cancer antigen-125 (CA-125) levels in patients with ovarian cancer and preoperative normalization of CA-125 levels after neoadjuvant chemotherapy (NAC). METHODS: The data of 103 patients with preoperative CA-125 normalization after NAC at the Yonsei Cancer Hospital (2006-2017) were analyzed. We compared the clinical characteristics and survival outcomes among patients with normal postoperative CA-125 levels and those with re-elevated CA-125 levels after interval debulking surgery (IDS). CA-125 elevation was defined as levels >35 U/mL. RESULTS: Among 103 patients, 52 (50.5%) and 51 (49.5%) had normal and re-elevated CA-125 levels after IDS, respectively. Patients with CA-125 re-elevation underwent more radical surgeries during IDS than those with normal CA-125 levels (p = 0.018). We found no significant differences in progression-free survival (PFS; p = 0.726) or overall survival (OS; p = 0.293) between the two groups. Moreover, patients with persistent CA-125 elevation (3 weeks after IDS) did not have inferior PFS (p = 0.171 and p = 0.208, respectively) or OS (p = 0.128 and p = 0.095, respectively) compared to patients with early normalization (within 3 weeks of IDS) or normal CA-125 levels. Multivariate regression showed that CA-125 re-elevation had no effect on recurrence (hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.43-1.30) or death (HR, 0.99; 95% CI, 0.33-2.98). CONCLUSION: Among patients with preoperative CA-125 normalization after NAC, postoperative CA-125 re-elevation had no prognostic value. Novel and reliable biomarkers reflecting the tumor response after IDS should be identified.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier-
dc.relation.isPartOfEJSO-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use-
dc.subject.MESHCA-125 Antigen/blood*-
dc.subject.MESHCarcinoma, Ovarian Epithelial/blood*-
dc.subject.MESHCarcinoma, Ovarian Epithelial/secondary-
dc.subject.MESHCarcinoma, Ovarian Epithelial/therapy*-
dc.subject.MESHChemotherapy, Adjuvant-
dc.subject.MESHCytoreduction Surgical Procedures-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoadjuvant Therapy-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHOvarian Neoplasms/blood*-
dc.subject.MESHOvarian Neoplasms/pathology-
dc.subject.MESHOvarian Neoplasms/therapy*-
dc.subject.MESHPreoperative Period-
dc.subject.MESHPrognosis-
dc.subject.MESHProgression-Free Survival-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSurvival Rate-
dc.titlePrognostic significance of CA-125 re-elevation after interval debulking surgery in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Obstetrics and Gynecology (산부인과학교실)-
dc.contributor.googleauthorYong Jae Lee-
dc.contributor.googleauthorYoung Shin Chung-
dc.contributor.googleauthorJung-Yun Lee-
dc.contributor.googleauthorEun Ji Nam-
dc.contributor.googleauthorSang Wun Kim-
dc.contributor.googleauthorSunghoon Kim-
dc.contributor.googleauthorYoung Tae Kim-
dc.identifier.doi10.1016/j.ejso.2018.10.053-
dc.contributor.localIdA00526-
dc.contributor.localIdA00595-
dc.contributor.localIdA00595-
dc.contributor.localIdA00729-
dc.contributor.localIdA00729-
dc.contributor.localIdA01262-
dc.contributor.localIdA01262-
dc.contributor.localIdA05165-
dc.contributor.localIdA05165-
dc.contributor.localIdA04638-
dc.contributor.localIdA04638-
dc.contributor.localIdA04849-
dc.contributor.localIdA04849-
dc.relation.journalcodeJ00847-
dc.identifier.eissn1532-2157-
dc.identifier.pmid30337203-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0748798318314537-
dc.subject.keywordCA-125-
dc.subject.keywordChemotherapy-
dc.subject.keywordInterval debulking surgery-
dc.subject.keywordOvarian cancer-
dc.subject.keywordPrognosis-
dc.contributor.alternativeNameKim, Sang Wun-
dc.contributor.affiliatedAuthor김상운-
dc.contributor.affiliatedAuthor김성훈-
dc.contributor.affiliatedAuthor김성훈-
dc.contributor.affiliatedAuthor김영태-
dc.contributor.affiliatedAuthor김영태-
dc.contributor.affiliatedAuthor남은지-
dc.contributor.affiliatedAuthor남은지-
dc.contributor.affiliatedAuthor이용재-
dc.contributor.affiliatedAuthor이용재-
dc.contributor.affiliatedAuthor이정윤-
dc.contributor.affiliatedAuthor이정윤-
dc.contributor.affiliatedAuthor정영신-
dc.contributor.affiliatedAuthor정영신-
dc.citation.volume45-
dc.citation.number4-
dc.citation.startPage644-
dc.citation.endPage649-
dc.identifier.bibliographicCitationEJSO, Vol.45(4) : 644-649, 2019-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.